Your browser is no longer supported. Please, upgrade your browser.
Settings
GEMP Gemphire Therapeutics Inc. daily Stock Chart
GEMP [NASD]
Gemphire Therapeutics Inc.
Index- P/E- EPS (ttm)-2.50 Insider Own34.00% Shs Outstand15.38M Perf Week-19.21%
Market Cap21.99M Forward P/E- EPS next Y-2.41 Insider Trans0.00% Shs Float10.90M Perf Month-37.28%
Income-29.30M PEG- EPS next Q-0.47 Inst Own41.30% Short Float10.46% Perf Quarter-81.64%
Sales- P/S- EPS this Y-25.40% Inst Trans27.83% Short Ratio1.19 Perf Half Y-74.69%
Book/sh1.06 P/B1.35 EPS next Y-19.90% ROA-107.70% Target Price3.33 Perf Year-84.92%
Cash/sh1.82 P/C0.79 EPS next 5Y- ROE-235.70% 52W Range0.83 - 11.43 Perf YTD-82.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-89.24% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low47.91% ATR0.21
Employees18 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)29.34 Volatility11.48% 10.17%
OptionableYes Debt/Eq0.68 EPS Q/Q52.60% Profit Margin- Rel Volume1.28 Prev Close1.43
ShortableYes LT Debt/Eq0.50 EarningsNov 12 AMC Payout- Avg Volume955.27K Price1.23
Recom2.50 SMA20-35.69% SMA50-32.59% SMA200-78.31% Volume248,711 Change-13.99%
Jan-26-18Reiterated H.C. Wainwright Buy $22 → $28
Oct-27-17Resumed Piper Jaffray Overweight $22
Oct-19-17Initiated ROTH Capital Buy
Aug-31-17Initiated H.C. Wainwright Buy $21
Aug-08-17Reiterated Jefferies Buy $32 → $18
Apr-10-17Initiated Piper Jaffray Overweight $30
Sep-25-18 08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga
Sep-24-18 05:06PM  Gemphire Therapeutics Announces Workforce Reduction GlobeNewswire
Aug-28-18 07:00AM  Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer GlobeNewswire
Aug-21-18 10:49AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Gemphire Therapeutics Inc. GlobeNewswire
Aug-13-18 04:01PM  Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire -7.78%
Aug-10-18 07:04AM  Gemphire Therapeutics stock plunges after trial halted due to 'unanticipated problems' MarketWatch -44.95%
06:00AM  Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD GlobeNewswire
Aug-07-18 08:23AM  The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel Benzinga -50.54%
Aug-06-18 04:01PM  Gemphire Provides Update On Development of Gemcabene GlobeNewswire
04:01PM  Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc. GlobeNewswire
Jun-29-18 09:01AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +94.47%
08:11AM  Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos Benzinga
08:10AM  Todays Research Reports on Stocks to Watch: Teva Pharmaceuticals and Gemphire Therapeutics ACCESSWIRE
Jun-28-18 04:01PM  Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients GlobeNewswire -5.07%
May-18-18 09:29AM  Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD GlobeNewswire
May-16-18 10:51AM  Why Gemphire Therapeutics Incs (NASDAQ:GEMP) Ownership Structure Is Important Simply Wall St. +14.05%
May-08-18 04:01PM  Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-03-18 04:01PM  Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer GlobeNewswire
Apr-12-18 04:01PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
Mar-16-18 03:16PM  Edited Transcript of GEMP earnings conference call or presentation 15-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
Mar-15-18 04:01PM  Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results GlobeNewswire
08:22AM  Gemphire Therapeutics Inc (NASDAQ:GEMP): Are Analysts Optimistic? Simply Wall St.
Mar-13-18 09:18AM  Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15 GlobeNewswire
Mar-08-18 08:00AM  Gemphire to Present at Two Investor Conferences GlobeNewswire -5.82%
Feb-27-18 04:01PM  Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH to be Rescheduled GlobeNewswire
Feb-26-18 10:45AM  Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock? Zacks
Feb-21-18 06:00AM  Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH GlobeNewswire
Feb-12-18 06:15PM  Gemphire Therapeutics Inc (GEMP) Interim President & CEO Steven R. Ph.d. ... GuruFocus.com
Feb-08-18 09:00AM  Gemphire Announces Pricing of $22 Million Public Offering of Common Stock GlobeNewswire -27.69%
Feb-07-18 04:32PM  Gemphire Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-31-18 04:01PM  Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD) GlobeNewswire
Jan-17-18 06:30AM  Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients GlobeNewswire +7.28%
Dec-29-17 07:45PM  What Should We Expect From Gemphire Therapeutics Incs (NASDAQ:GEMP) Earnings In The Years Ahead? Simply Wall St.
Dec-26-17 07:00AM  Blog Exposure - Gemphire Therapeutics Launches Clinical Program for Developing Gemcabene as Treatment for NASH/NAFLD ACCESSWIRE
Dec-21-17 06:00AM  Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program GlobeNewswire
Nov-22-17 06:00AM  Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences GlobeNewswire
Nov-13-17 01:30PM  Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-02-17 07:00AM  Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock Marketwired
Oct-23-17 08:00AM  Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017 GlobeNewswire
Sep-25-17 09:00AM  Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit GlobeNewswire
Sep-19-17 04:01PM  Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development GlobeNewswire +5.93%
Sep-18-17 08:00AM  Gemphire to Present at Cantor Fitzgerald Global Healthcare Conference on September 26 in New York GlobeNewswire
Sep-14-17 04:36PM  Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene GlobeNewswire
Aug-14-17 06:00AM  Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Aug-07-17 11:57AM  Gemphire Therapeutics Inc. (Nasdaq: GEMP) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire -46.78%
10:00AM  Gemphire to Present at the Canaccord Genuity Growth Conference 2017 GlobeNewswire
06:00AM  Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients GlobeNewswire
Aug-01-17 04:30PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -7.31%
Jul-25-17 08:00AM  Gemphire Enters Into $15 Million Term Loan Agreement With Silicon Valley Bank GlobeNewswire
Jul-14-17 08:15AM  Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 9.7% Zacks
Jun-28-17 04:01PM  Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients GlobeNewswire
Jun-01-17 08:00AM  Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference GlobeNewswire +8.69%
May-31-17 09:41AM  Stocks to Watch: Amazon, Alphabet, Michael Kors, Gemphire Therapeutics The Wall Street Journal
May-30-17 04:01PM  Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch GlobeNewswire
May-09-17 06:00AM  Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-04-17 02:21PM  Gemphire to Host Key Opinion Leader Lunch on the Evolving NASH Landscape GlobeNewswire
May-01-17 06:00AM  Gemphire to Present at ATVB|PVD 2017 Scientific Sessions GlobeNewswire
Mar-29-17 04:30PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Mar-24-17 01:04PM  GEMPHIRE THERAPEUTICS INC. Financials
10:48AM  Gemphire Therapeutics (GEMP) is in Overbought Territory: What's Next? Zacks
Mar-23-17 08:35AM  Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 12% Zacks
Mar-21-17 09:17AM  Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization GlobeNewswire
06:06AM  GEMPHIRE THERAPEUTICS INC. Files SEC form 10-K, Annual Report
Mar-16-17 03:52PM  Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event GlobeNewswire +5.41%
Mar-15-17 04:30PM  Gemphire Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
04:08PM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q4 2016 Gemphire Therapeutics Inc Earnings Release - After Market Close
Mar-13-17 05:10PM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
06:30AM  Gemphire Therapeutics to Report Fiscal Year End 2016 Financial Results on Wednesday, March 15 GlobeNewswire
Mar-10-17 09:34AM  Gemphire Therapeutics Announces $12.5 Million Financing GlobeNewswire
09:26AM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial
Feb-07-17 06:31AM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-03-17 04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides Investor's Business Daily
04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides
Feb-02-17 06:00AM  Gemphire Therapeutics to Participate in the Canaccord Genuity Rare Disease and Biopharma 1 on 1 Day and the RBC Capital Markets Global Healthcare Conference GlobeNewswire
Jan-30-17 06:00AM  Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial GlobeNewswire
Jan-18-17 05:00PM  Gemphire Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-09-17 08:00AM  Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study GlobeNewswire
Jan-05-17 08:40AM  Gemphire Therapeutics Provides Clinical Update GlobeNewswire
Jan-04-17 03:40PM  LifeSci Capital Initiates Coverage of Gemphire Therapeutics Accesswire
Dec-20-16 12:03AM  How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers at Insider Monkey
Dec-19-16 02:00PM  Three Appealing Micro-Cap Stocks
Nov-29-16 04:15PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-16 11:07AM  CORRECTING and REPLACING Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia GlobeNewswire
06:00AM  Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia GlobeNewswire
Nov-17-16 04:01PM  Gemphire Therapeutics to Present at the Piper Jaffray Healthcare and LD Micro Main Event Conferences GlobeNewswire
Nov-02-16 07:07AM  Q3 2016 Gemphire Therapeutics Inc Earnings Release - Time Not Supplied
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH. The company was founded in 2008 and is headquartered in Livonia, Michigan.